Overexpression of the 170 kDa transmembrane transporter P-glycoprotein (P-gp) has been implicated in multidrug resistance (MDR) associated with an accelerated outward drug transport (Gottesman and Pastan, 1993) . Recently, new mediators of MDR were identified in P-gp-negative tumour cells resistant to doxorubicin (DOX), indicating differential mechanisms of drug extrusion. The 190 kDa multidrug resistance-associated protein (MRP), a novel member of the ABC transporters, appears to precede P-gp activation or to function solely in MDR clones (Cole et al., 1992; Flens et al., 1994; Eijdems et al., 1995) . The MRP and P-gp efflux pumps confer a similar MDR phenotype (Cole et al., 1994) , whereas the 190 kDa transporter seems to possess a reduced substrate specificity for the fluorescent dye rhodamine 123 and the competitive inhibitor verapamil (McGrath et al., 1989; Barrand et al., 1993 ). An alternative mechanism of anthracycline sequestration away from nuclear targets is supposed to involve the vacuolar system and vesicular secretory traffic (Beck, 1987) . The latter model is in agreement with the following observations: increased membrane exocytosis in MDR cells (Sehested et al., 1987) ; anthracycline accumulation in vesicular compartments (Gervasoni et al., 1991; Coley et al., 1993) ; restoration of cellular or nuclear drug accumulation induced by the protonophores nigericin and monensin (Marquardt and Center, 1992) , by the inhibitor of vesicular exocytosis brefeldin A (BFA), and by the H+-ATPase inhibitor bafilomycin Al . Several P-gp-negative MDR tumour cell lines and secretory epithelia were reported to overexpress the 110 kDa lung resistance-related protein (LRP), a vesicle marker with unknown function (Scheper et al., 1993) . Whatever putative mediators are found overexpressed in MDR clones, the major problem to resolve is their relevance to clinical drug resistance. Indeed, inherent DOX resistance of solid tumours apparent within drug concentrations achievable in plasma may not be conferred by P-gp, which is normally activated in vitro under high selection pressure of over 500 nM DOX at continuous exposure. The early stages in MDR selection are likely to provide more valuable insights into mechanisms of drug extrusion operating in chemoresistant tumours.
In a preliminary report we showed that MDR in the human pancreatic tumour PSN1/ADR cells selected by intermittent exposure to 170 nM DOX was not the result of P-gp expression, and that increased DOX efflux in these cells was inhibited by BFA (Verovski et al., 1994) . BFA is a potent inhibitor of vesicle budding and exocytosis . It disrupts the downstream GDP/GTP signal towards the ADP-ribosylation factor (ARF), a monomeric GTP-binding (G) protein, triggering vesicle budding ). An upstream regulation of vesicle budding implicates heterotrimeric G proteins sensitive to fluoroaluminate, an agent that abrogates the GDP/GTP exchange by mimicking the y-phosphor in GTP (Barr et al., 1991) . Thus, BFA and fluoroaluminate can be considered as probes for the G protein-controlled vesicular traffic whose possible function in drug trapping and extrusion may be to adjunct the ATP-dependent drug translocations through the P-gp and MRP efflux pumps. The anterograde transport of vesicles is driven along cytoskeletal microtubules and can therefore be inhibited by nocodazole, a microtubuledisrupting agent (Breitfeld et al., 1990) .
Based on the hypothesis that G protein-dependent drug transport pathways may contribute to low-level DOX resistance, we took a further step to characterise the immunocytochemical and pharmacological profile of the PSN1/ADR cells. Therefore, the evolution of DOX resistance, P-gp/MRP expression and the effects of BFA and fluoroaluminate on DOX accumulation have been analysed in several PSN1/ADR sublines stepwise selected in clinically relevant drug concentrations. The MDR phenotype of PSN1/ADR cells was verified using a broad spectrum of anti-tumour drugs. In addition, the mechanisms of DOX extrusion in the MRP-positive PSN1/ADR and the P-gp- (Scheper et al., 1988 (Scheper et al., , 1993 Maillet et al., 1993) . All studies were carried out in early confluent cultures on plastic tissue culture plates (Greiner, Frickenhausen, Germany).
Immunostaining
To perform immunostaining, cells were fixed with 4% paraformaldehyde and permeabilised with 0.1% saponin. Pgp, LRP and MRP were stained respectively with monoclonal antibodies JSB-1 (Scheper et al., 1988) , LRP-56 (Scheper et al., 1993) and MRPm6 (Flens et al., 1994) Cytotoxicity assays The drug cytotoxicity (IC50) at continuous exposure was estimated by a 5 day MTT assay as described previously (Delvaeye et al., 1993) . The surviving fraction (SF) of cells exposed to DOX for 4 h was assessed by a modified MTT serial dilution assay carried out as follows. Confluent cultures of PSN1 and PSN1/ADR cells were exposed to DOX at concentrations indicated in the legends, washed with PBS and harvested by trypsinisation. Six serial dilutions (0.5 log-fold) of the cell suspension, starting from 104 cells per well, were reseeded into a 96-well plate and incubated for 5 days. The MTT assay was performed for 3 h at 37°C in 80 pl of fresh medium containing 0.5 mg ml-' MTT [3-
The reaction was stopped by careful addition of 200,l of DMSO -0.05 M HCl. The formazan crystals were dissolved in the lower layer of DMSO during 5-10 min at 37°C. Afterwards the DMSO and medium layers were mixed by repeated pipetting and the absorbency was measured at 540 nm. The surviving fraction (SF) was calculated as the dilution factor of the control that produced the same optical density as the treated samples.
Doxorubicin accumulation
Cell cultures were exposed to 1 jg ml-' DOX alone or with modulators at specified concentrations for 4 h at 37°C and washed with PBS on ice. The incubation period of 4 h was selected in preliminary experiments as the end point, corresponding to a steady-state cellular drug concentration. The cellular DOX content was estimated by a fluorometric assay in a 50% ethanol/0.05 N HCI extract and normalised to DNA (ng DOX pg-' DNA) as described previously (Delvaeye et al., 1993) . We preferred to use the DNA content rather than the cell count to normalise the DOX uptake because the adherent cells were fixed by the ethanol extraction procedure and therefore difficult to resuspend.
Doxorubicin retention
The cell cultures were exposed to 10 jg ml-' DOX for 1 h at 37°C, washed with PBS and reincubated for 2 h at 37°C in drug-free medium with modulators at the indicated concentrations. The incubation time of 2 h was selected in preliminary experiments as the end point providing a reasonable divergence of the drug retention-time curves for PSN1 and PSN1/ADR cells. Afterwards, the cells were washed with PBS on ice and processed for analysis of the cellular DOX content as in the DOX accumulation experiments. The cellular DOX content after a 1 h uptake was taken as 100%.
Rhodamine 123 uptake Cell cultures were exposed to 0.2 ug ml-' rhodamine 123 for 1 h at 37°C, washed with cold PBS and trypsinised. The intracellular rhodamine 123 content was analysed by flow cytometry in a FACS 4.
ECL Western immunoblotting
Cells were lysed in a buffer containing 137 mM sodium chloride, 20 mM Tris-HCl (pH 8.0), 1% triton X-100, 0.5% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulphonyl fluoride, 1 jig ml-' aprotinin and 1 jg ml-' pepstatin. The lysates were sonicated, clarified for 20 min at 13 000 g and mixed 1:4 (vol/vol) with a standard SDS/2-mercaptoethanolcontaining sample buffer. The protein extracts from 105 cells were resolved in an SDS/PAGE using a 7.5% resolving gel (1.5 mm thickness), and electrophoretically transferred onto Hybond-C super nitrocellulose membrane (Amersham, Buckinghamshire, UK). The membranes were stained for 1 h at 20°C with the primary monoclonal antibodies to P-gp (JSB-1, 1:300) and MRP (MRPm6, 1:100 (Figure 3) . These kinetics were similar in all of the PSN1/ADR sublines (data not shown). The H134AD cells originally selected in 1700 nM DOX overexpressed P-gp (Figure 2 ) in agreement with literature (Scheper et al., 1988) . The latter cells were used in this study as a model of P-gp-mediated DOX resistance.
Flow cytometry of the rhodamine 123 uptake
The fluorescent dye rhodamine 123 is thought to be a relevant probe for the P-gp efflux pump and provides a sensitive functional assay, alternative to immunostaining approaches (Gottesman and Pastan, 1993) . Indeed, the CV) The protein samples extracted from 105 cells were resolved in a 7.5% polyacrylamide gel containing 0.1% SDS. The blots were probed for P-gp and MRP with the monoclonal antibodies JSB-1 and MRPm6 respectively and analysed by an immunoperoxidasebased ECL technique. The position of all blanks (not exposed to rhodamine 123) was adjusted to that of the H134 cells.
rhodamine 123 uptake was significantly reduced in the P-gppositive H134AD cells relative to the H134 cells (Figure 4) . To compare the FACS data, all blank samples (not exposed to rhodamine 123) were adjusted to that of H134 cells by tuning the amplification of the fluorescence signal. In contrast to H134AD cells the rhodamine 123 signal in the MRPpositive PSN1/ADR sublines was close to that of the parental cell line PSNI, although for the PSN1/ADR33 cells we observed a somewhat decreased rhodamine 123 uptake. This comparison confirms the low activity of the P-gp pump in PSN1/ADR cells as expected from the immunostaining experiments (Figures 1 and 2) .
Drug cross-resistance in PSNI/ADR cells The PSNI/ADR33 cells selected in 170 nM DOX demonstrated an MDR phenotype with classical cross-resistance to natural cytotoxins including etoposide, vincristine and actinomycin D (Table I ). The resistance index (7.6-to 39-fold) between the PSNI/ADR33 and PSNI cells could not be attributed to any differences in growth rate since both cell lines possessed the same doubling time of 21+2 h. A much lower resistance index was observed for colchicine and rhodamine 123, being respectively 4.3 and 3.9. There was also a weak cross-resistance (3.1-fold) to cisplatin, a drug that is not normally involved in MDR. BFA and genistein did not show cross-resistance to DOX and revealed spectacular difference in cytotoxicity at continuous exposure in contrast to growth inhibition effects at a short-term exposure (see below). classical MTT assay. Therefore, confluent cultures of PSN1 and PSN1/ADR33 cells were exposed to DOX and chemomodifiers for 4 h and afterwards the cells were reseeded to assess the cell survival ( were exposed to doxorubicin alone at 0.1 and 1.0 Mg ml'-respectively or in combination with brefeldin A or verapamil at the specified concentrations. bSI, the sensitisation index, was calculated by dividing the SF for doxorubicin alone by the SF for doxorubicin plus chemomodifier. CP<0.01 compared with doxorubicin alone.
Effects of brefeldin
PSN1/ADR33 cells. The effects of fluoroaluminate and genistein should be interpreted with caution since they are somewhat cytotoxic at modulatory concentrations (data not shown). It is worth noting that verapamil was a rather nonspecific inhibitor of the DOX efflux in both drug-resistant cell lines, and was unexpectedly more active in the MRP-positive PSN1/ADR33 cells. However, the restoration of DOX retention by verapamil in the latter cells did not result in a substantial chemosensitisation, as shown in Table II effects of all inhibitors in these cells were below 25% and are not presented here. The comparison of DOX accumulationretention patterns in the PSNI and PSNI/ADR33 cells clearly demonstrated an accelerated drug extrusion as the mechanism of reduced drug accumulation and acquired DOX resistance.
Discussion
Selection of the human pancreatic tumour cell line PSN1/ ADR in 17-510 nM DOX activated various MDR markers and mechanisms of drug resistance without inducing a detectable level of P-gp. In both flow cytometry and ECL Western blot immunostaining the PSN1/ADR33 cells adapted to 170 nM DOX at intermittent exposure displayed a rise in MRP only. The P-gp efflux pump remained undetectable by the rhodamine 123 functional assay (Gottesman and Pastan, 1993) . The DOX accumulationretention defects in the MRP-positive PSN1/ADR33 cells were reversible by the vesicle traffic inhibitors BFA and fluoroaluminate. In contrast, in the P-gp-overexpressing H134AD cells adapted to 1700 nM DOX at continuous exposure (Scheper et al., 1988) , rhodamine 123 uptake was significantly decreased, while both BFA and fluoroaluminate failed to inhibit DOX extrusion. Therefore, our data suggest that the BFA/fluoroaluminate-sensitive mechanism of DOX extrusion plays a role in low-level DOX resistance associated with the MRP transporter, but may be attenuated in highly resistant clones possessing the more efficient P-gp efflux pump. A prevalent role of MRP over P-gp in early steps of MDR acquisition emerged in recent literature (Eijdems et al., 1995) . Another early MDR marker found in P-gp-negative MDR clones seems to be LRP (Scheper et al., 1993) , which we observed already in PSN1/ADR7.3 cells selected in 17-51 nM DOX. While the function of LRP is not known, the MRP transporter can confer broad-spectrum MDR (Cole et al., 1994) , and is likely to underlie the MDR phenotype of PSN1/ADR33 cells. The MRP-positive PSN1/ADR33 cells exhibit an MDR spectrum similar to P-gp-mediated MDR (Gottesman and Pastan, 1993) except for an unusual crossresistance to cisplatin, reported also for the P-gp-negative N592/DX cells (Supino et al., 1993) .
The reversal effects of chemomodifiers in 190 kDa/MRPoverexpressing cells appear to be reduced and more variable than in P-gp-positive MDR cells (McGrath et al., 1989; Barrand et al., 1993; Versantvoort et al., 1993; Cole et al., 1994) . In our experiments with MRP-positive PSN1/ADR33 cells the reversal effect of verapamil on DOX resistance was modest relative to the magnitude of acquired resistance. In the parental PSN1 cells verapamil also demonstrated sensitising effects, whereas BFA caused chemoprotection. The latter effect has been previously described in L1210 cells (Vichi and Tritton, 1993) . Important findings are that BFA possesses a reversing activity similar to that of verapamil in PSN1/ADR33 cells, and that concentrations of BFA up to 320 gM are not directly cytotoxic after a time period of 2-4 h. In short-term experiments with the P-gp-negative MDR COR-L23/R cells BFA was reported to be cytotoxic already at 40 giM and was therefore not regarded as a potential MDR reverser, although it did increase the cellular drug accumulation and the nuclearcytoplasmic ratio for anthracyclines . The reason for this discrepancy remains to be elucidated, but we cannot exclude that BFA toxicity is cell line dependent. It is also possible that BFA provoked more cell detachment in the sparse cultures used by Rhodes et al. (1994) than in the confluent cultures in our protocol.
To provide new insights into the multifactorial nature of MDR more functional probes addressed to non-P-gpmediated drug transport are needed. Genistein was recently proposed as a probe for non-P-gp-related drug accumulation defects, although cytotoxicity at the modulatory concentrations of 100-300 ,UM was observed (Versantvoort et al, 1993 ).
Genistein appears to be a competitive inhibitor of anthracycline transport attributed to the MRP efflux pump (Versantvoort et al., 1994) . This mechanism could account for the genistein-sensitive drug accumulation defects in the MRP-positive PSNI/ADR33 cells presented here, and in a variety of MRP-positive MDR cell lines (GLC4/ADR, SW-1573/2R120, HT1080/DR4, HL60/ADR) described elsewhere (Versantvoort et al., 1993) . However, the reversal of DOX resistance by genistein was reported also for the MRPnegative K562/TPA cells, thereby indicating the existence of target(s) different from MRP (Takeda et al., 1994) . Additionally, ATP depletion (Versantvoort et al., 1994) and the inhibition of the G protein-linked secretory pathway (Duan et al., 1994) were observed in cells exposed to genistein at high concentrations. BFA has not yet been studied extensively as a chemomodifier of DOX resistance. Our data demonstrates that BFA is capable of complete discrimination between ADR extrusion pathways in MRP-positive PSNI/ADR33 and P-gp-positive H134AD cells. Its specificity and potency seem to be close to those of genistein. The reversal of DOX resistance by BFA in PSN1/ADR33 cells is optimal at 100-320 giM, whereas in cells not selected for MDR the inhibition of vesicular traffic by BFA occurs already at 10 giM . This discrepancy raises the question of whether BFA is a specific enough probe to implicate drug-trapping vesicles in the mechanism of DOX extrusion. A striking similarity between the inhibitory potency of BFA and genistein in the MRP-positive PSN1/ADR33 cells would suggest that BFA, by analogy to genistein (and verapamil), might be a competitive inhibitor of the MRP efflux pump. This assumption is in line with the concomitant activation of MRP and the outward DOX transport sensitive to genistein, BFA and verapamil. However, the inhibitory effects of verapamil can also be attributed to membrane traffic perturbations (Sehested et al., 1987) . In addition, the above explanation is not consistent with the opposite effects of BFA and verapamil on DOX cytotoxicity in parental PSN1 cells that displayed a low but detectable level of MRP. Secondly, DOX extrusion in PSN1/ADR33 cells was sensitive to fluoroaluminate, an agent which disrupts GTP-dependent vesicular transport (Barr et al., 1991) , and is unlikely to exert preferential inhibition of MRP compared with P-gp when its interference with ATP-binding sites is supposed. Thirdly, nocodazole, an agent that can block the vesicular transport by microtubule depolymerisation (Breitfeld et al., 1990) , inhibited substantially the DOX extrusion in the PSNI/ ADR33 but not H134AD cells. Finally, PSN1/ADR96 cells adapted to 510 nM DOX retained BFA-sensitive DOX accumulation defects whereas MRP declined. Hence, it seems unlikely that BFA would target solely the MRP transporter in this cell subline.
In the extensive literature now available on BFA its target is thought to be the ARF GDP/GTP exchange factor, specifically ascribed to G protein-controlled vesicular traffic Klausner et al., 1992) . Interestingly, the activated pool of G proteins in a GTP-bound form was shown to resist low concentrations of BFA Ktistakis et al., 1992) . Therefore, elevated modulatory concentrations of BFA in PSN1/ADR33 cells might indicate an enriched pool of activated G proteins that trigger vesicular exocytosis. In the view of this hypothesis, BFA-sensitive vesicular transport could particularly sustain DOX resistance, since lipophilic and weakly basic anthracyclines can be trapped inside vesicular structures (Gervasoni et al., 1991; Coley et al., 1993) . Future studies should clarify whether the model of vesicle-mediated drug transport is relevant to the BFA/fluoroaluminate-sensitive mechanism of DOX extrusion or whether BFA is an inhibitor of MRP. In this paper, we focused primarily on reversal properties of G proteintargeting agents in an effort to provide a rationale for searching for novel functional probes of MDR not associated with the P-gp transporter. Our preliminary tests have shown a clear correlation (r> 0.9) between the BFA reversal effects and DOX resistance in a panel of P-gp-negative human pancreatic tumour cell lines (Verovski et al., 1994) . This is further support for BFA as an appropriate tool to dissect the mechanisms of DOX resistance not associated with the P-gp efflux pump.
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